For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer.

ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis.

Among the 560 proteases encoded in the human genome, the metalloprotease A Disintegrin and Metalloprotease 17 (ADAM17) has gained much attention in recent years and has emerged as a central regulatory hub in inflammation, immunity and cancer development.

Aug 21, 2019 · In this review, we discuss recent research implicating ADAM17 as a key player in the development of LAC, and highlight the potential of ADAM17 inhibition as a promising therapeutic strategy to tackle this deadly malignancy.

Several studies have examined the effects of inhibiting ADAM17 or CD16A cleavage directly during NK cell engagement of antibody-coated tumor cells, which resulted in strengthened antibody tethering, decreased tumor cell detachment, and enhanced CD16A signaling and cytokine production.

Here we examine how ectodomain shedding of these molecules can alter their biology and impact on immune and inflammatory responses and cancer development. Gene targeting of Adam17 is embryonic lethal, highlighting the importance of ectodomain shedding during development.

Oct 12, 2016 · Additionally, elevated EGFR signalling caused by excess ADAM17 activity is associated with cancer progression 1. Hence, ADAM17 represents an important potential therapeutic target.

Jun 26, 2024 · ADAM17 inhibition led to elevated CD122 expression and enhanced response to IL-2 and IL-15 stimulation in both mouse and human CD8 + T cells. Intriguingly, inhibition of ADAM17 in CD8 + T cells...

Jun 1, 2019 · Among the 560 proteases encoded in the human genome, the metalloprotease A Disintegrin and Metalloprotease 17 (ADAM17) has gained much attention in recent years and has emerged as a central regulatory hub in inflammation, immunity and cancer development.

Aug 4, 2023 · Together, these findings highlight the diverse pro-tumorigenic roles of ADAM17 in various cancer types, providing insights into potential therapeutic strategies targeting ADAM17 for cancer treatment.